Zonjero delivers laboratory-grade tirzepatide in a high-capacity 30mg / 3ml pre-filled pen – the gold-standard dual incretin mimetic designed for advanced research into synergistic GLP-1 and GIP receptor signaling, profound metabolic remodeling, and superior body weight regulation.

Tirzepatide is a first-in-class dual GLP-1 / GIP receptor agonist with a balanced affinity profile and engineered fatty diacid side chain for exceptional pharmacokinetic stability (half-life ≈ 5 days), enabling once-weekly administration in research models.

Major research domains include:

• Synergistic enhancement of glucose-dependent insulin secretion and suppression of glucagon release
• Powerful central and peripheral appetite suppression leading to substantial caloric reduction
• Delayed gastric emptying and prolonged satiety signaling
• Unmatched body weight reduction in multiple clinical-phase studies (frequently 20–25% mean loss at higher doses over 72 weeks)
• Superior improvements in insulin sensitivity and glycemic control compared to single GLP-1 agonists
• Significant reductions in visceral adipose tissue, liver fat content, and markers of metabolic inflammation
• Favorable cardiometabolic profile: improvements in lipid parameters, blood pressure, and cardiovascular risk markers

The 30mg strength in a 3ml pen provides generous dosing flexibility for longer-term protocols, dose-escalation studies, or experiments requiring higher exposure levels.

Product highlights:

• Exceptional purity tirzepatide (>99% – third-party COA verified)
• Sterile, ready-to-use pre-filled pen format – precise delivery and maximum lab convenience
• Advanced molecular design for prolonged activity and stability